Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
Identifieur interne : 000F15 ( PubMed/Corpus ); précédent : 000F14; suivant : 000F16Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
Auteurs : M. Péchevis ; C E Clarke ; P. Vieregge ; B. Khoshnood ; C. Deschaseaux-Voinet ; G. Berdeaux ; M. ZieglerSource :
- European journal of neurology [ 1351-5101 ] ; 2005.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (economics), Depression (epidemiology), Depression (etiology), Dyskinesias (economics), Dyskinesias (etiology), Dyskinesias (psychology), Europe, Female, Health Care Costs, Humans, Levodopa (adverse effects), Levodopa (economics), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics), Parkinson Disease (psychology), Quality of Life.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , economics : Antiparkinson Agents, Levodopa.
- geographic : Europe.
- drug therapy : Parkinson Disease.
- economics : Dyskinesias, Parkinson Disease.
- epidemiology : Depression.
- etiology : Depression, Dyskinesias.
- psychology : Dyskinesias, Parkinson Disease.
- Activities of Daily Living, Aged, Female, Health Care Costs, Humans, Male, Middle Aged, Quality of Life.
Abstract
The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias). This 6-month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form-36 (SF-36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF-36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery-Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias.
DOI: 10.1111/j.1468-1331.2005.01096.x
PubMed: 16324089
Links to Exploration step
pubmed:16324089Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.</title><author><name sortKey="Pechevis, M" sort="Pechevis, M" uniqKey="Pechevis M" first="M" last="Péchevis">M. Péchevis</name><affiliation><nlm:affiliation>CEMKA-EVAL, Bourg-la-Reine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C E" last="Clarke">C E Clarke</name></author><author><name sortKey="Vieregge, P" sort="Vieregge, P" uniqKey="Vieregge P" first="P" last="Vieregge">P. Vieregge</name></author><author><name sortKey="Khoshnood, B" sort="Khoshnood, B" uniqKey="Khoshnood B" first="B" last="Khoshnood">B. Khoshnood</name></author><author><name sortKey="Deschaseaux Voinet, C" sort="Deschaseaux Voinet, C" uniqKey="Deschaseaux Voinet C" first="C" last="Deschaseaux-Voinet">C. Deschaseaux-Voinet</name></author><author><name sortKey="Berdeaux, G" sort="Berdeaux, G" uniqKey="Berdeaux G" first="G" last="Berdeaux">G. Berdeaux</name></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M" last="Ziegler">M. Ziegler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16324089</idno><idno type="pmid">16324089</idno><idno type="doi">10.1111/j.1468-1331.2005.01096.x</idno><idno type="wicri:Area/PubMed/Corpus">000F15</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.</title><author><name sortKey="Pechevis, M" sort="Pechevis, M" uniqKey="Pechevis M" first="M" last="Péchevis">M. Péchevis</name><affiliation><nlm:affiliation>CEMKA-EVAL, Bourg-la-Reine, France.</nlm:affiliation></affiliation></author><author><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C E" last="Clarke">C E Clarke</name></author><author><name sortKey="Vieregge, P" sort="Vieregge, P" uniqKey="Vieregge P" first="P" last="Vieregge">P. Vieregge</name></author><author><name sortKey="Khoshnood, B" sort="Khoshnood, B" uniqKey="Khoshnood B" first="B" last="Khoshnood">B. Khoshnood</name></author><author><name sortKey="Deschaseaux Voinet, C" sort="Deschaseaux Voinet, C" uniqKey="Deschaseaux Voinet C" first="C" last="Deschaseaux-Voinet">C. Deschaseaux-Voinet</name></author><author><name sortKey="Berdeaux, G" sort="Berdeaux, G" uniqKey="Berdeaux G" first="G" last="Berdeaux">G. Berdeaux</name></author><author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M" last="Ziegler">M. Ziegler</name></author></analytic><series><title level="j">European journal of neurology</title><idno type="ISSN">1351-5101</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (economics)</term><term>Depression (epidemiology)</term><term>Depression (etiology)</term><term>Dyskinesias (economics)</term><term>Dyskinesias (etiology)</term><term>Dyskinesias (psychology)</term><term>Europe</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (economics)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (economics)</term><term>Parkinson Disease (psychology)</term><term>Quality of Life</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Depression</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term><term>Aged</term><term>Female</term><term>Health Care Costs</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias). This 6-month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form-36 (SF-36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF-36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery-Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16324089</PMID><DateCreated><Year>2005</Year><Month>12</Month><Day>05</Day></DateCreated><DateCompleted><Year>2006</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1351-5101</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur. J. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.</ArticleTitle><Pagination><MedlinePgn>956-63</MedlinePgn></Pagination><Abstract><AbstractText>The treatment of Parkinson's disease (PD) with l-DOPA leads to involuntary movements (dyskinesias). This 6-month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form-36 (SF-36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF-36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery-Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Péchevis</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEMKA-EVAL, Bourg-la-Reine, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Vieregge</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Khoshnood</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Deschaseaux-Voinet</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Berdeaux</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ziegler</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Trial Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020820" MajorTopicYN="N">Dyskinesias</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="Y">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16324089</ArticleId><ArticleId IdType="pii">ENE1096</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2005.01096.x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:16324089
|texte= Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16324089" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |